Between January 1989 and June 1997, 533 patients (423 male, 110 female, mean age 61 years, range 22-89 years) with hepatocellular carcinoma (HCC) were observed at our center. We report on 419 patients retrospectively compared for different treatments: liver transplantation (LT; 55 patients), resective surgery (RS; 41 patients), transarterial chemoembolization (TACE; 171 patients) and percutaneous ethanol injection (PEI; 152 patients). The 3- and 5-year actuarial survival rates were, respectively, 72\% and 68\% for LT, 64 and 44\% for RS, 54 and 36\% for PEI, and 32 and 22\% for TACE. Survival curves were compared for sex, age, tumor characteristics, alphafetoprotein level, Child class, and etiology of cirrhosis. All patient-related characteristics examined (sex, age) are not significantly related to patient survival. Tumor-related variables and associated liver disease variables significantly conditioned survival in relation to different treatments. LT seems to be the treatment of choice for monofocal HCC less then 5 cm in diameter and in selected cases of plurifocal HCC.
Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization / G., Colella; R., Bottelli; L. D., Carlis; C. V., Sansalone; G. F., Rondinara; A., Alberti; L. S., Belli; F., Gelosa; G. M., Iamoni; A., Rampoldi; A. D., Gasperi; A., Corti; E., Mazza; P., Aseni; A., Meroni; A. O., Slim; M., Finzi; DI BENEDETTO, Fabrizio; F., Manochehri; M. L., Follini; G., Ideo; D., Forti. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - STAMPA. - 581:(1998), pp. 419-438.
Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection, and chemoembolization.
DI BENEDETTO, Fabrizio;
1998
Abstract
Between January 1989 and June 1997, 533 patients (423 male, 110 female, mean age 61 years, range 22-89 years) with hepatocellular carcinoma (HCC) were observed at our center. We report on 419 patients retrospectively compared for different treatments: liver transplantation (LT; 55 patients), resective surgery (RS; 41 patients), transarterial chemoembolization (TACE; 171 patients) and percutaneous ethanol injection (PEI; 152 patients). The 3- and 5-year actuarial survival rates were, respectively, 72\% and 68\% for LT, 64 and 44\% for RS, 54 and 36\% for PEI, and 32 and 22\% for TACE. Survival curves were compared for sex, age, tumor characteristics, alphafetoprotein level, Child class, and etiology of cirrhosis. All patient-related characteristics examined (sex, age) are not significantly related to patient survival. Tumor-related variables and associated liver disease variables significantly conditioned survival in relation to different treatments. LT seems to be the treatment of choice for monofocal HCC less then 5 cm in diameter and in selected cases of plurifocal HCC.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
